The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
Open accessAbstract
BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes. METHODS: In this phase 3, placebo-controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death. RESULTS: Over a median of 18.2 months, the primary outcome occurred in 386 of 2373 patients (16.3%) in the dapagliflozin group and in 502 of 2371 patients (21.2%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). A first worsening heart failure event occurred in 237 patients (10.0%) in the dapagliflozin group and in 326 patients (13.7%) in the placebo group (hazard ratio, 0.70; 95% CI, 0.59 to 0.83). Death from cardiovascular causes occurred in 227 patients (9.6%) in the dapagliflozin group and in 273 patients (11.5%) in the placebo group (hazard ratio, 0.82; 95% CI, 0.69 to 0.98); 276 patients (11.6%) and 329 patients (13.9%), respectively, died from any cause (hazard ratio, 0.83; 95% CI, 0.71 to 0.97). Findings in patients with diabetes were similar to those in patients without diabetes. The frequency of adverse events related to volume depletion, renal dysfunction, and hypoglycemia did not differ between treatment groups. CONCLUSIONS: Among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular causes was lower among those who received dapagliflozin than among those who received placebo, regardless of the presence or absence of diabetes. (Funded by AstraZeneca; DAPA-HF ClinicalTrials.gov number, NCT03036124.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, 55% of patients in this trial did not have diabetes at baseline, and the effect of dapagliflozin was similar at any hemoglobin A1c level.40”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the secondary outcome of worsening kidney function (de fi ned as a sustained $ 50% reduction in eGFR, kidney failure, or death from kidney causes) occurred in 1.2% of the dapagli fl ozin arm and 1.6% of the placebo arm (HR: 0.71; 95% CI: 0.44 -1.16), which was not statistically signi fi cant ( P ¼ 0.17).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [100]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the DAPA-HF trial, major hypoglycemia, lower-limb amputation, and fracture occurred infrequently and the incidences were similar between the 2 treatment groups.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [100]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2 inhibitors reduce the incidence of heart failure and improve heart failurerelated outcomes, including hospitalization for heart failure and heart failure-related symptoms, in people with diabetes with preserved or reduced ejection fraction (250,(255)(256)(257)(298)(299)(300)(301)(302)(303)(304)(305)(306).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [299]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The lower risk of hospitalization for heart failure or death from cardiovascular causes in the dapagliflozin group than in the placebo group is consistent with the results of two previous trials of dapagliflozin, the DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58) and DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure”
From Dapagliflozin in Patients with Chronic Kidney Disease (2020) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“SGLT2 inhibition is also known to benefit patients with heart failure and a reduced ejection fraction.471”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [471]
The cited source says what the claim attributes to it.
In the citing paper
“Over a median 18-month follow-up of 4744 patients with HFrEF, treatment with dapagliflozin significantly reduced the composite primary end point of time to first worsening of HF or death from CV causes (hazard ratio [HR], 0.74 [95% CI 0.65-0.85]; P < 0.001), as well as HHF (HR, 0.70 [95% CI 0.59 - 0.83]) and CV death (HR, 0.82 [95% CI 0.69 - 0.98]).”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“SGLT2 inhibitor treatment was safe with no excess in hypovolemia, hypoglycemia, or renal side effects compared with placebo.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“The primary outcome was similarly reduced for individuals with or without diabetes, with no effect of heterogeneity by diabetes status.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [100]
The cited source says what the claim attributes to it.
In the citing paper
“The primary outcome was also similar among those with an eGFR $ 60 ml/min per 1.73 m 2 (HR: 0.76; 95% CI: 0.63 -0.92) or < 60 ml/min per 1.73 m 2 (HR: 0.72; 95% CI: 0.59 -0.86).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [100]
The cited source says what the claim attributes to it.
In the citing paper
“the primary outcome of cardiovascular death, heart failure hospitalization, or urgent heart failure visit occurred in 16.3% of the dapagli fl ozin group and 21.2% of the placebo group (HR: 0.74; 95% CI: 0.65 -0.85).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [100]
The cited source says what the claim attributes to it.
In the citing paper
“However, notably, SGLT2i have been studied among patients without T2D who have CKD in the DAPA-CKD trial (and the soonto-be-published EMPA-KIDNEY trial) or who have heart failure (in the DAPA-HF, EMPEROR-Reduced, and EMPEROR-Preserved trials) and did not confer any increased risk of severe hypoglycemia or diabetic ketoacidosis among individuals without T2D.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [100]
The cited source says what the claim attributes to it.
In the citing paper
“The effect of dapagliflozin on the primary outcome was consistent regardless of the presence or absence of type 2 diabetes (299).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [299]
The cited source says what the claim attributes to it.
In the citing paper
“lower risk of first worsening heart failure event (HR 0.70 [95% CI 0.59-0.83]),”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [299]
The cited source says what the claim attributes to it.
In the citing paper
“Dapagliflozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65-0.85]),”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [299]
The cited source says what the claim attributes to it.
In the citing paper
“The effect of dapagliflozin on the primary outcome was consistent regardless of the presence or absence of type 2 diabetes (287).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [287]
The cited source says what the claim attributes to it.
In the citing paper
“Dapagliflozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65–0.85]), lower risk of first worsening heart failure event (HR 0.70 [95% CI 0.59–0.83]), and lower risk of cardiovascular death (HR 0.82 [95% CI 0.69–0.98]) compared with placebo.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [287]
In the citing paper
“Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the risk of hospitalizations for heart failure in 8 large-scale trials, including those that focused on type 2 diabetes, heart failure with a reduced ejection fraction, and chronic kidney disease.1–8”
From Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial (2021) · cites this paper as [6]
In the citing paper
“Rates of worsening heart failure or cardiovascular death are lower among patients with heart failure who are treated with dapagliflozin and empagliflozin regardless of diabetes diagnosis.7,8”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [7]
In the citing paper
“As for the morbidity, renal outcome and HHF, it was clear that SGLT-2i had more significant impact than finerenone, which might be explained by the special potency of SGLT-2i such as reducing blood glucose, reducing oxidative stress, losing weight, reducing uric acid, controlling blood pressure and improving renal ultrafiltration and hypoxia [65, 71–79].”
In the citing paper
“In DAPA-HF, dapagliflozin reduced the risk for worsening HF or CVD death irrespective of diabetes status (58).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [58]
In the citing paper
“Rates of heart failure hospitalization have been improved in recent trials including people with type 2 diabetes, most of whom also had ASCVD, with sodium -glucose cotransporter 2 (SGLT2) inhibitors (8 -11).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [11]
In the citing paper
“Over a median of 18.2 months, the group assigned to dapagli fl ozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65 -0.85]), lower risk of fi rst worsening heart failure event (HR 0.70 [95% CI 0.59 -0.83]), and lower risk of cardiovascular death (HR 0.82 [95% CI 0.69 -0.98]) compared with placebo.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [11]
In the citing paper
“The effect of dapagli fl ozin on the primary outcome was consistent regardless of the presence or absence of type 2 diabetes (11).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [11]
In the citing paper
“Over a median of 18.2 months, the group assigned to dapagli fl ozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65 -0.85]), lower risk of fi rst worsening heart failure event (HR 0.70 [95% CI 0.59 -0.83]), and lower risk of cardiovascular death (HR 0.82 [95% CI 0.69 -0.98]) compared with placebo.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [11]
In the citing paper
“Over a median of 18.2 months, the group assigned to dapagli fl ozin treatment had a lower risk of the primary outcome (HR 0.74 [95% CI 0.65 -0.85]), lower risk of fi rst worsening heart failure event (HR 0.70 [95% CI 0.59 -0.83]), and lower risk of cardiovascular death (HR 0.82 [95% CI 0.69 -0.98]) compared with placebo.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [11]
In the citing paper
“In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure), the SGLT2 inhibitor dapagliflozin reduced the incidence of the primary composite outcome of cardiovascular death or worsening heart failure (HF) in patients who had HFrEF with and without type 2 diabetes.”
From Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF (2021) · cites this paper as [9]
In the citing paper
“The DAPA-HF trial randomly assigned patients with HFrEF with and without type 2 diabetes in a double-blind, placebo-controlled, event-driven trial.”
From Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationCanagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,031
Honigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1966 · Cited by 127
Park, S., Farooq, M. A., Gaertner, S., Bruckert, C., Qureshi, A. W., Lee, H.-H., Benrahla, D., Pollet, B., Stéphan, D., Ohlmann, P., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-00997-7 · Cited by 129
Chen, W., Zhang, Y., Wang, Z., Tan, M., Lin, J., Qian, X., Li, H., & Jiang, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1078205 · Cited by 127
Tanaka, H., Soga, F., Tatsumi, K., Mochizuki, Y., Sano, H., Toki, H., Matsumoto, K., Shite, J., Takaoka, H., Doi, T., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0985-z · Cited by 130
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Pabel, S., Hamdani, N., Luedde, M., & Sossalla, S. T. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00529-8 · Cited by 142
Non‐alcoholic fatty liver disease and type 2 diabetes: An update
Lee, C., Lui, D. T. W., & Lam, K. S. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13756 · Cited by 139
Ibrahim, M., Davies, M. J., Ahmad, E., Annabi, F. A., Eckel, R. H., Ba-Essa, E. M., El Sayed, N. A., Hess Fischl, A., Houeiss, P., Iraqi, H., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001248 · Cited by 124
SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function
Maejima, Y. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00186 · Cited by 133
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
Shen, L., Kristensen, S. L., Bengtsson, O., Böhm, M., de Boer, R. A., Docherty, K. F., Inzucchi, S. E., Katova, T., Køber, L., Kosiborod, M., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2020.11.009 · Cited by 125
Self-citationAtualização de Tópicos Emergentes da Diretriz Brasileira de Insuficiência Cardíaca – 2021
Marcondes‐Braga, F. G., Moura, L. Z., Issa, V. S., Vieira, J. L., Rohde, L. E. P., Simões, M. V., Fernandes-Silva, M. M., Rassi, S., Martins, S. M., de Albuquerque, D. C., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210367 · Cited by 169
Ma, L., Zou, R., Shi, W., Zhou, N., Chen, S., Zhou, H., Chen, X., & Wu, Y. (2022) · Theranostics · doi:10.7150/thno.75121 · Cited by 125
Nicolau, J. C., Feitosa, G. S., Petriz, J. L. F., Furtado, R. H. D. M., Précoma, D. B., Lemke, W., Lópes, R. D., Timerman, A., Marin‐Neto, J. A., Bezerra, L., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210180 · Cited by 162
Self-citationThe Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients
Lim, J., Kwon, S., Jeon, Y., Kim, Y., Kwon, H., Kim, D. K., Lee, H., Kim, Y.-L., Kim, C., Park, S.-H., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004228 · Cited by 131
Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2021) · Diabetes · doi:10.2337/dbi20-0040 · Cited by 123
Hsieh, P., Chu, P., Cheng, H., Huang, Y., Chou, W.-C., Tsai, K., & Chan, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710146 · Cited by 123
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Kim, N. H., Seo, J. A., Kim, M. K., Lim, J. H., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0282 · Cited by 130
Judge, P., Staplin, N., Mayne, K., Wanner, C., Green, J., Hauske, S. J., Emberson, J., Preiss, D., Ng, S., Roddick, A., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00322-4 · Cited by 137
Current and future therapeutic perspective in chronic heart failure
Mascolo, A., di Mauro, G., Cappetta, D., Angelis, A. D., Torella, D., Urbanek, K., Berrino, L., Nicoletti, G. F., Capuano, A., & Rossi, F. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106035 · Cited by 131
Hundertmark, M., Adler, A., Antoniades, C. A., Coleman, R. L., Griffin, J. L., Holman, R. R., Lamlum, H., Lee, J., Massey, D., Miller, J. J. J. J., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062021 · Cited by 129
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care
Choi, H. K., McCormick, N., & Yokose, C. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00725-9 · Cited by 125
Personalized type 2 diabetes management: an update on recent advances and recommendations
Williams, D. M., Jones, H., & Stephens, J. W. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s331654 · Cited by 121
Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy
Palmer, B. F., & Clegg, D. J. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.17621120 · Cited by 134
Pierce, J. B., Vaduganathan, M., Fonarow, G. C., Ikeaba, U., Chiswell, K., Butler, J., DeVore, A. D., Heidenreich, P. A., Huang, J., Kittleson, M. M., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.1266 · Cited by 120
Self-citationXu, J., Kitada, M., Ogura, Y., Liu, H., & Koya, D. (2021) · Cells · doi:10.3390/cells10061457 · Cited by 125
Effects of canagliflozin on human myocardial redox signalling: clinical implications
Kondo, H., Akoumianakis, I., Badi, I., Akawi, N. A., Kotanidis, C. P., Polkinghorne, M., Stadiotti, I., Sommariva, E., Antonopoulos, A. S., Carena, M. C., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab420 · Cited by 121
Chen, J., Wei, X., Zhang, Q., Wu, Y., Xia, G., Xia, H., Wang, L., Shang, H., & Lin, S. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.005 · Cited by 128
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease
Zhou, Z., Jardine, M., Li, Q., Neuen, B. L., Cannon, C. P., de Zeeuw, D., Edwards, R., Levin, A., Mahaffey, K. W., Perkovic, V., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.031623 · Cited by 124
Cannon, C. P., Perkovic, V., Agarwal, R., Baldassarre, J., Bakris, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044359 · Cited by 117
Li, X., Lü, Q., Qiu, Y., do Carmo, J. M., Wang, Z., da Silva, A. A., Mouton, A. J., Omoto, A. C. M., Hall, M. E., Li, J., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.018298 · Cited by 117
Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
Bode, D., Semmler, L., Wakula, P., Hegemann, N., Primeßnig, U., Beindorff, N., Powell, D. R., Dahmen, R., Ruetten, H., Oeing, C. U., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01208-z · Cited by 116
Sibony, R. W., Segev, O., Dor, S., & Raz, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417147 · Cited by 151
Polycystic Ovary Syndrome: Pathophysiology and Therapeutic Opportunities
Dong, J., & Rees, D. A. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000548 · Cited by 123
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.046 · Cited by 113
Empagliflozin Inhibits Na+/H+ Exchanger Activity in Human Atrial Cardiomyocytes
Trum, M., Riechel, J., Lebek, S., Pabel, S., Sossalla, S. T., Hirt, S. W., Arzt, M. E., Maier, L. S., & Wagner, S. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13024 · Cited by 115
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease
Mantovani, A., Byrne, C. D., Benfari, G., Bonapace, S., Simon, T. G., & Targher, G. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.007 · Cited by 115
Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
Gao, Y.-M., Feng, S., Wen, Y., Tang, T., Wang, B., & Liu, B. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104215 · Cited by 125
von Haehling, S., Arzt, M. E., Doehner, W., Edelmann, F., Evertz, R., Ebner, N., Herrmann‐Lingen, C., Garfias‐Veitl, T., Koziolek, M. J., Noutsias, M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1838 · Cited by 119
Perry, R. J., & Shulman, G. I. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.008387 · Cited by 121
Bakaeen, F. G., Gaudino, M. F. L., Whitman, G. R., Doenst, T., Ruel, M., Taggart, D. P., Stulak, J. M., Benedetto, U., Anyanwu, A., Chikwe, J., et al. (2021) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.04.052 · Cited by 117
Pandey, A. K., Bhatt, D. L., Pandey, A. K., Marx, N., Cosentino, F., Pandey, A., & Verma, S. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad389 · Cited by 125
Self-citationDiabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
Wilcox, T., Block, C. E. M. D., Schwartzbard, A. Z., & Newman, J. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.056 · Cited by 124
Renin-angiotensin system and inflammation update
Cantero‐Navarro, E., Fernández‐Fernández, B., Ramos, A. M., Rayego‐Mateos, S., Rodrigues-Díez, R. R., Sánchez-Niño, M. D., Sanz, A. B., Ruiz‐Ortega, M., & Ortíz, A. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111254 · Cited by 119
Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis
Masson, W. M., Cobo, A. L., & Nogueira, J. P. (2021) · Cells · doi:10.3390/cells10082150 · Cited by 118
Kim, D., Seo, J., Choi, K. H., Lee, S. H., Choi, J., Jeon, E., & Yang, J. H. (2023) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2022.11.002 · Cited by 118
Impact Analysis of Heart Failure Across European Countries: An ESC-HFA Position Paper
Rosano, G. M. C., Seferovic, P. M., Savarese, G., Spoletini, I., Lopatin, Y. M., Gustafsson, F., Bayés‐Genís, A., Jaarsma, T., Abdelhamid, M., González, A., et al. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14076 · Cited by 120
Self-citationDesign, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
The EMPA-KIDNEY Collaborative Group, Herrington, W. G., Wanner, C., Green, J. B., Hauske, S. J., Judge, P., Mayne, K. J., Ng, S. Y. A., Sammons, E., Zhu, D., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac040 · Cited by 110
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
Palmiero, G., Cesaro, A., Vetrano, E., Pafundi, P. C., Galiero, R., Caturano, A., Moscarella, E., Gragnano, F., Salvatore, T., Rinaldi, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115863 · Cited by 124
Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin
Grotta, R. L., de Candia, P., Olivieri, F., Matacchione, G., Giuliani, A., Rippo, M. R., Tagliabue, E., Mancino, M., Rispoli, F., Ferroni, S., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04289-z · Cited by 121
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
Dabour, M. S., George, M. Y., DANIEL, M. R., Blaes, A. H., & Zordoky, B. N. M. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.01.007 · Cited by 119
Sharma, A., Pagidipati, N. J., Califf, R. M., McGuire, D. K., Green, J. B., DeMets, D., George, J. T., Gerstein, H. C., Hobbs, T. M., Holman, R. R., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041022 · Cited by 111
Self-citationPacker, M. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01041-4 · Cited by 113
Jensen, J., Omar, M., Kistorp, C., Poulsen, M. K., Tuxen, C., Gustafsson, I., Køber, L., Gustafsson, F., Faber, J. O., Fosbøl, E. L., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.07.011 · Cited by 112
Self-citationSalah, H. M., Alaref, S. J., Khan, M. S., Al‐Hawwas, M., Vallurupalli, S., Mehta, J. L., Mounsey, J. P., Greene, S. J., McGuire, D. K., Lópes, R. D., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.10.064 · Cited by 112
Wiciński, M., Wódkiewicz, E., Górski, K. M., Walczak, M., & Malinowski, B. (2020) · Pharmaceuticals · doi:10.3390/ph13110379 · Cited by 111
Management of Heart Failure Patient with CKD
Banerjee, D., Rosano, G., & Herzog, C. A. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14180920 · Cited by 117
Qiu, M., Ding, L., Zhang, M., & Zhou, H. (2021) · Diabetes and Vascular Disease Research · doi:10.1177/14791641211011016 · Cited by 113
Hoong, C. W. S., & Chua, M. W. J. (2021) · Endocrinology · doi:10.1210/endocr/bqab079 · Cited by 112
Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
Elrakaybi, A., Laubner, K., Zhou, Q., Hug, M. J., & Seufert, J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101549 · Cited by 118
Giugliano, D., Longo, M., Scappaticcio, L., Bellastella, G., Maiorino, M. I., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01430-3 · Cited by 115
Avula, V. R., Sharma, G. V., Kosiborod, M., Vaduganathan, M., Neilan, T. G., López‐Fernández, T., Dent, S. F., Baldassarre, L. A., Scherrer‐Crosbie, M., Barac, A., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.08.026 · Cited by 113
Self-citationLin, D. S.-H., Lee, J.-K., Hung, C.-S., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05529-w · Cited by 108
SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
Fernández‐Fernández, B., Sarafidis, P. A., Kanbay, M., Navarro‐González, J. F., Soler, M. J., Górriz, J. L., & Ortíz, A. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfaa198 · Cited by 108
Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
Januzzi, J. L., Zannad, F. M., Anker, S. D., Butler, J., Filippatos, G. S., Pocock, S., Ferreira, J. P., Sattar, N. A., Verma, S., Vedin, O., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.046 · Cited by 108
Self-citation10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 107
Parizo, J. T., Goldhaber‐Fiebert, J. D., Salomon, J. A., Khush, K. K., Spertus, J. A., Heidenreich, P. A., & Sandhu, A. T. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.1437 · Cited by 111
Glycated Hemoglobin and Subclinical Atherosclerosis in People Without Diabetes
Rosselló, X., Raposeiras‐Roubín, S., Oliva, B., Sánchez‐Cabo, F., García-Ruiz, J. M., Caimari, F., Mendiguren, J. M., Lara‐Pezzi, E., Bueno, H., Fernández‐Friera, L., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.03.335 · Cited by 110
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure
McMurray, J. J. V., Wheeler, D. C., Stefánsson, B. V., Jongs, N., Postmus, D., Correa‐Rotter, R., Chertow, G. M., Hou, F. F., Rossing, P. R., Sjöström, C. D., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2021.06.017 · Cited by 109
Self-citationRelationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction
Salah, H. M., Pandey, A., Soloveva, A. E., Abdelmalek, M. F., Diehl, A. M., Moylan, C. A., Wegermann, K., Rao, V. N., Hernandez, A. F., Tedford, R. J., et al. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.07.010 · Cited by 110
Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction
Udell, J. A., Jones, W. S., Petrie, M. C., Harrington, J., Anker, S. D., Bhatt, D. L., Hernandez, A. F., & Butler, J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.03.353 · Cited by 110
Self-citationMetra, M., Adamo, M., Tomasoni, D., Mebazaa, A., Bayés‐Genís, A., Abdelhamid, M., Adamopoulos, S. N., Anker, S. D., Bauersachs, J. K., Belenkov, Y. N., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2888 · Cited by 114
Self-citationDas, N. A., Carpenter, A. J., Belenchia, A. M., Aroor, A. R., Noda, M., Siebenlist, U. K., Chandrasekar, B., & DeMarco, V. G. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109506 · Cited by 109
Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.036 · Cited by 112
Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future
Wintrich, J., Kindermann, I., Ukena, C., Selejan, S., Werner, C. M., Maack, C., Laufs, U., Tschöpe, C., Anker, S. D., Lam, C. S. P., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01633-w · Cited by 106
Self-citationMcGovern, A. P., Hogg, M., Shields, B. M., Sattar, N. A., Holman, R. R., Pearson, E. R., Hattersley, A. T., Jones, A. G., & Dennis, J. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001238 · Cited by 107
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure
Emdin, M., Aimo, A., Castiglione, V., Vergaro, G., Georgiopoulos, G. A., Saccaro, L. F., Lombardi, C., Passino, C., Cerbai, E., Metra, M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.031 · Cited by 107
Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction
Omar, M., Jensen, J., Frederiksen, P. H., Kistorp, C., Videbæk, L. M., Poulsen, M. K., Möller, S., Ali, M., Gustafsson, F., Køber, L., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.005 · Cited by 106
Self-citationDefects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy
Previs, M. J., O’Leary, T. S., Morley, M. P., Morley, M. P., Palmer, B., Lewinter, M., Pagani, F. D., Pagani, F. D., Petucci, C., Kim, M., et al. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009521 · Cited by 108
Applications of SGLT2 inhibitors beyond glycaemic control
O’Hara, D. V., Lam, C. S. P., McMurray, J. J. V., Yi, T. W., HOCKING, S. L., Dawson, J., Raichand, S., Januszewski, A. S., & Jardine, M. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00836-y · Cited by 123
Self-citationWong, N. D., Toth, P. P., & Amsterdam, E. A. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.013 · Cited by 105
Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis
Yafasova, A., Fosbøl, E. L., Schou, M., Gustafsson, F., Rossing, K., Bundgaard, H., Lauridsen, M. D., Kristensen, S. L., Torp-Pedersen, C. T., Gislason, G., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.06.038 · Cited by 108
Self-citationEngler, C., Leo, M., Pfeifer, B. E., Juchum, M., Chen-Koenig, D., Pölzl, K., Schoenherr, H., Vill, D., Oberdanner, J., Eisendle, E., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001279 · Cited by 103
eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined
Meraz-Muñoz, A., Weinstein, J. J., & Wald, R. (2021) · Kidney360 · doi:10.34067/kid.0001172021 · Cited by 111
The Combination of Beta-Blockers and ACE Inhibitors Across the Spectrum of Cardiovascular Diseases
Strauss, M. H., Hall, A. S., & Narkiewicz, K. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07248-1 · Cited by 113
Selvaraj, S., Fu, Z., Jones, P. G., Kwee, L. C., Windsor, S. L., Ilkayeva, O., Newgard, C. B., Margulies, K. B., Husain, M., Inzucchi, S. E., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.060402 · Cited by 104
Self-citationPatorno, E., Htoo, P. T., Glynn, R. J., Schneeweiss, S., Wexler, D. J., Pawar, A., Bessette, L. G., Chin, K., Everett, B. M., & Kim, S. C. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0893 · Cited by 103
Theofilis, P., Sagris, Μ., Oikonomou, E. K., Antonopoulos, A. S., Siasos, G., Tsioufis, K. P., & Tousoulis, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109080 · Cited by 108
Tanaka, A., Hisauchi, I., Taguchi, I., Sezai, A., Toyoda, S., Tomiyama, H., Sata, M., Ueda, S., Oyama, J., Kitakaze, M., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12707 · Cited by 101
Self-citationChen, H.-Y., Huang, J., Siao, W.-Z., & Jong, G. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01048-x · Cited by 104
Zanchi, A., Burnier, M., Muller, M., Wurzner-Ghajarzadeh, A., Maillard, M. P., Loncle, N., Milani, B., Dufour, N., Bonny, O., & Pruijm, M. T. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016173 · Cited by 102
Effect of dapagliflozin on anaemia in DAPA‐HF
Docherty, K. F., Curtain, J. P., Anand, I. S., Bengtsson, O., Inzucchi, S. E., Køber, L., Kosiborod, M., Langkilde, A. M., Martínez, F. A., Ponikowski, P. P., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2132 · Cited by 104
Self-citationArterial hypertension – Clinical trials update 2021
Ghorani, H. A., Götzinger, F., Böhm, M., & Mahfoud, F. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.007 · Cited by 121
Self-citationGlucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101
Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
Hou, Y., Zheng, C., Yen, T., & Lu, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217833 · Cited by 110
Abraham, W. T., Psotka, M. A., Fiuzat, M., Filippatos, G. S., Lindenfeld, J. M., Mehran, R., Ambardekar, A. V., Carson, P. E., Jacob, R., Januzzi, J. L., et al. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.10.002 · Cited by 108
Self-citationHeart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
Ceriello, A., Catrinoiu, D., Chandramouli, C., Cosentino, F., Dombrowsky, A. C., Itzhak, B., Lalic, N. M., Prattichizzo, F., Schnell, O., Seferovic, P. M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01408-1 · Cited by 110
Pulmonary hypertension associated with left heart disease
Maron, B. A., Bortman, G., Marco, T. D., Huston, J., Lang, I. M., Rosenkranz, S. L., Vachiéry, J., & Tedford, R. J. (2024) · European Respiratory Journal · doi:10.1183/13993003.01344-2024 · Cited by 110
Accelerated and personalized therapy for heart failure with reduced ejection fraction
Shen, L., Jhund, P. S., Docherty, K. F., Vaduganathan, M., Petrie, M. C., Desai, A. S., Køber, L., Schou, M., Packer, M., Solomon, S. D., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac210 · Cited by 102
Self-citationAtrial fibrillation: comorbidities, lifestyle, and patient factors
Shantsila, E., Choi, E., Lane, D. A., Joung, B., & Lip, G. Y. H. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100784 · Cited by 108
Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction
Bavendiek, U., Großhennig, A., Schwab, J., Berliner, D., Rieth, A. J., Maier, L. S., Gaspar, T., Thomas, N. H., Liu, X., Schallhorn, S., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2415471 · Cited by 100
Self-citationThe cytokine storm of COVID-19: a spotlight on prevention and protection
Pearce, L., Davidson, S. M., & Yellon, D. M. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1783243 · Cited by 99
Metadata
- Authors
- McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., Desai, A. S., Diez, M., Drozdz, J., Dukát, A., Ge, J., Howlett, J. G., Katova, T., Kitakaze, M., Ljungman, C. E. A., Merkely, B., Nicolau, J. C., O’Meara, E., Petrie, M. C., Vinh, P. N., Schou, M., Tereshchenko, S., Verma, S., Held, C., DeMets, D. L., Docherty, K. F., Jhund, P. S., Bengtsson, O., Sjöstrand, M., & Langkilde, A.-M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom (J.J.V.M., M.C.P., K.F.D., P.S.J.); the Cardiovascular Division (S.D.S., A.S.D.) and the TIMI Study Group, Brigham and Women’s Hospital and Harvard Medical School (M.S.S.) — all in Boston; Section of Endocrinology, Yale University School of Medicine, New Haven, CT (S.E.I.); Rigshospitalet Copenhagen University Hospital (L.K.) and the Department of Cardiology, Gentofte University Hospital (M. Schou),...
- Semmelweis University (HU)
- Uppsala University (SE)
- ORCID
- McMurray, John J.V.
- Solomon, Scott D.
- Inzucchi, Silvio E.
- Køber, Lars
- Kosiborod, Mikhail N.
- Ponikowski, Piotr
- Sabatine, Marc S.
- Anand, Inder S.
- Bělohlávek, Jan
- Böhm, Michael
- Chiang, Chern-En
- Chopra, Vijay K.
- Desai, Akshay S.
- Ge, Junbo
- Howlett, Jonathan G.
- Kitakaze, Masafumi
- Ljungman, Charlotta E.A.
- Merkely, Béla
- O’Meara, Eileen
- Petrie, Mark C.
- Schou, Morten
- Tereshchenko, Sergey
- Verma, Subodh
- Held, Claes
- DeMets, David L.
- Docherty, Kieran F.
- Jhund, Pardeep S.
- Bengtsson, Olof
- Sjöstrand, Mikaela
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-11-21
- Volume
- 381
- Issue
- 21
- Pages
- 1995-2008
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2974260792
- Semantic Scholar
- 43e5c9ff37bb98a622e70cb01c55e23a60782d69
- Cited by
- 7,140
- References
- 21
- Citations by year
- 2026: 842 · 2025: 955 · 2024: 979 · 2023: 1060 · 2022: 1138 · 2021: 1152 · 2020: 904 · 2019: 89
- FWCI
- 593.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Research Bank (Australian Catholic University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- AstraZeneca Plc
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- dapagliflozin, SGLT2 inhibitors, heart failure with reduced ejection fraction, type 2 diabetes, cardiovascular mortality, heart failure hospitalization, hypovolemia, renal dysfunction, hypoglycemia, SGLT2 inhibition, heart failure prognosis, adverse events, glucose monitoring, heart failure with preserved ejection fraction
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Benzhydryl Compounds, Cardiovascular Agents, Cardiovascular Diseases, Combined Modality Therapy, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Glucosides, Heart Failure, Glycated Hemoglobin, Hospitalization, Humans, Male, Middle Aged, Stroke Volume, Ventricular Dysfunction, Left, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
